Tuesday, 28 February 2023, 15:00-16:30 CET
Cooperation among pharma companies, patients, and patient organisations can bring significant public health benefits.
In building strong partnerships, it is important that all parties openly share their views about the relevance and benefit of their collaboration.
Cooperation among all relevant stakeholders is particularly crucial at this point in time during the implementation period of the EU Health Technology Assessment (HTA) Directive, which was just revised and gives more room to the patients and health care professionals (HCPs) throughout the process. More patients and HCPs need to know about the HTA process, the directive, and the benefit they can gain from actively participating in the process.
In order to support the development or strengthening the cooperation among all relevant stakeholders and better understand the role that patients can play in the process, Pancreatic Cancer Europe and Cancer Patients Europe are organising a webinar to exchange views on how best to enhance the cooperation on the HTA process.
The event takes place online on Tuesday, 28 February 2023, from 15:00 to 16:30 CET.
It aims to exchange views on the best cooperation among relevant stakeholders on the HTA process.
- Pharma companies
- Patients and patient advocates
- HTA bodies, payers, and regulators
- PCE’s members
- Medical societies
- Other interested stakeholders
15:00 Tit Albreht, Moderator: Opening
15:05 MEP Tomislav Sokol, EU Parliamentary Intergroup Challenge Cancer: Welcome message
15:15 Maya Matthews, European Commission: Keynote speech on The European Directive on Health Technology Assessment
15:30 Panel discussion: Opportunities and challenges of the HTA process
- Jean Yves Blay, European Society of Medical Oncology (ESMO), Belgium (TBC)
- Ansgar Hebborn, The European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
- Antonella Cardone, Cancer Patients Europe (CPE), Belgium
- Elaine Julian, The European Access Academy (EAA)
- Ali Stunt, Pancreatic Cancer Action, United Kingdom
16:20 Alfredo Carrato, Chair of PCE Board of Directors: Conclusions and final remarks
16:30 Closing of the event
The event is supported by
PCE maintains its independency and full editorial control on any materials produced or published